Research Article

Prevalence of Rifampicin Resistance among Presumptive Pulmonary Tuberculosis Patients within Lagos and its Environs in South-Western Nigeria

Davies-Bolorunduro O.F.1*, Nduaga S.J.1, Abiodun A.T1, Amuda, B.O.1, Osuolale, K.A2, Atoe K.2, Cadmus S1
1 Center for Tuberculosis Research (CTBR), Department of Microbiology, Nigerian Institute of Medical Research (NIMR), Yaba, Lagos State
2 Monitoring and Evaluation Unit (Biostatistics), Nigerian Institute of Medical Research (NIMR), Yaba, Lagos State.
* Corresponding author: bizdave1@gmail.com
Published: Jun, 2020
DOI: 10.67614/njm.2020.uv6dair4
Pages: 5188-5196

Abstract

Drug resistance (DR) is a major global health concern and currently implicated in fuelling the burden of multi-drug resistant tuberculosis (MDR-TB) in Nigeria. Overall, DR poses serious public health threat to TB control programmes particularly in TB endemic countries with limited resources. However, early and rapid detection of rifampicin resistance (RR), a surrogate marker for MDR-TB is important to reduce treatment period and transmission; with the overall goal of reducing the burden of the disease. The study successfully determined the prevalence of RR Mycobacterium tuberculosis (MTB) among presumptive pulmonary TB patients in Lagos and its environs. A retrospective study involving 1,453 TB patients was conducted using data extracted from the clinical register of presumptive TB patients screened for MTB and RR-TB using Xpert MTB/RIF assay at the Centre for Tuberculosis Research, Nigerian Institute of Medical Research (NIMR) between January, 2018 and August, 2019. The data was analysed using Statistical Package for Social Sciences (SPSS) version 23. Result shows that the overall prevalence of TB was 15.3% (222/1453). MTB infection was detected in 79 locations out of which eight had a high prevalence (15.7%-26.1%) of the disease. Notably, from the patients, RR-TB was 5.9% (13/222) among all TB confirmed cases, with four (30.8%) being females and those infected ranging from 22 to 75 years (34.85±15.01) years; with one person (male) being co-infected with HIV. This study highlights the prevalence of 5.9% rifampicin-resistance among pulmonary TB patients in the urban and peri-urban areas of Lagos, South-Western Nigeria.

Keywords

Prevalence Rifampicin-resistance Mycobacterium tuberculosis GeneXpert.

References

  1. Adejumo O.A, Olusola-Faleye B., Adepoju V, Bowale A., Adesola V, Falana A, Owuna H, Otemuyiwa K., Oladega S. and Adegboye O. (2017). Prevalence of rifampicin resistant Mycobacterium tuberculosis in Nasarawa State, Nigeria. Niger J Basic Clin Sci, 14:21-5.
  2. Akpaka, P. E. Tulloch-Reid, M., Justiz-Vaillant, A. and Smikle, M. F. (2006). Prevalence of human immunodeficiency virus infection in patients with pulmonary tuberculosis at the National Chest Hospital in Jamaica, Rev Panam Salud Publ, 19: 38–43.
  3. Ateqa B., Menbere F. and Getachew Y. (2019). Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infectious Diseases, 19:307. https://doi.org/10.1186/s12879-019-3943-1
  4. Atashi, S, Izadi, B., Jalilian, S., Madani, S.H., Farahani, A. and Mohajeri, P. (2017). Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran. New Microbes and New Infections, 19:117-120.
  5. Audu E.S, Gambo M.S, Yakubu A.A. (2017). Rifampicin resistant Mycobacterium tuberculosis in Nasarawa State, Nigeria. Niger J Basic Clin Sci, 2: 81-87.
  6. Barun Mathema, Jason R Andrews, Ted Cohen, Martian W Borgdorff, Marcel Behr, Judith R Glynn, Roxana Rustomjee, Benjamin J Silk, Robin Wood, Drivers of Tuberculosis Transmission, The Journal of Infectious Diseases, 216(6) 644–653, https://doi.org/10.1093/infdis/jix354
  7. Boehme C.C, Nabeta P., Hillemann D., Nicol M.P., Shenai S., Krapp F. et al. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med., 363:1005-1015
  8. Coovadia Y.M., Mahomed S., Pillay M., Werner L., Mlisana K. (2013). Rifampicin Mono Resistance in Mycobacterium tuberculosis in Kwazulu Natal, South Africa: A significant phenomenon in high prevalence TB/HIV Region. PLoS One.,8:77712.
  9. Dereje A.G., Yoseph C.M., Adugua N.G., Gizachew T.A, Melaku T.D, Kassu D.T. (2015). Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in Remote healthcare facilities. BMC Microbiol.,15: 220. doi: 10.1186/s12866-015-0566-6
  10. Egbe K, Ike A.C., Aleruchi C. (2016). Prevalence of tuberculosis and rifampicin resistance among patients seeking medical care in Nasarawa State, North Central Nigeria. Science Journal of Public Health.4:3, 214-218. doi: 10.11648/j.sjph.20160403.17
  11. Fadeyi A., Desalu O.O, Ugwuoke C., Opanwa O.A, Nwabuisi C., Salami A.K. (2017). Prevalence of rifampicin-resistant tuberculosis among patients previously treated for pulmonary tuberculosis in North-Western, Nigeria. Nig Med J, 58:61-6
  12. Gyar, S. D., Dauda, E. and Reuben, C. R. (2014). Prevalence of Tuberculosis in HIV/AIDS patients in Lafia, central Nigeria. Int J Curr Microbiol Appl Sc, 3: 831-838.
  13. Huang W.L, Chen H.Y, Kuo Y.M, Jou R. (2009). Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol., 47(8): 2520-4.
  14. Ibrahim, K. O. O. Akanni, and U. J. Ijah, (2004). The prevalence of tuberculosis in HIV patients in Minna metropolis, Nig J Microbiol, vol. 18: 212-216.
  15. Idigbe O, Sofola T, Akinosho R, Onwujekwe D, Odiah F. (1998). Initial drug resistance tuberculosis amongst HIV seropositive and sero-negative prison inmates in Lagos, Nigeria. Int Conf AIDS, 12:137.
  16. Ikaube P.O. and Ebuenyi I.D., (2018). Prevalence of rifampicin resistance by automated Genexpert rifampicin assay in patients with pulmonary tuberculosis in Yenagoa, Nigeria. The Pan African Medical Journal, 28:204
  17. Iliyasu, Z. and Babashani, M. (2009). Prevalence and Predictors of TB coinfection Among HIV seropositive patients attending Aminu Kano Teaching Hospital, Northern Nigeria, J. Epid., 2: 81-87.
  18. Lagos State Government. (2012). Abstract of Local Government Statistics. <http://mepb.lagosstate.gov.ng/wp-content/uploads/sites/29/2017/01/ABSTRACT-OF-LOCAL-GOVERNMENT-STATISTICS-2016.pdf>
  19. Nyamogoba H, D. N., Mbuthia, Gikuvi, M, Mpoke, S. and Waiyaki P. G. (2012). A high tuberculosis and human immunodeficiency virus co-infection rate and clinical significance of non-tuberculous mycobacteria in Western Kenya, Afr J Health Sc, Vol. 21: 147-154.
  20. Onipede, A. O. , Idigbe, O., Ako-Nai, A. K., Omojola, O., Oyelese, A. O., Abodenin, A. O., Komolafe, A. O. and Wemambu, S. N. C. (1999). Seroprevalence of TB antibodies in TB patients in Ile-Ife, Afr med J, 76: 127-132.
  21. Onyedum CC, Alobu I, Ukwaja KN (2017) Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
  22. Prasad, R., Gupta, N., & Banka, A. (2018). Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. Lung India : official organ of Indian Chest Society, 35(1), 78–81. https://doi.org/10.4103/lungindia.lungindia_98_17
  23. Tadesse, S. and Tadesse, T. (2013). Co-infection of tuberculosis patients in Dabat, northwest Ethiopia. J Infect Dis Immun, 5:29-32.
  24. United Nations Development Programme (UNDP). Retrieved 2020-06-14, from <http://hdr.undp.org/en/countries/profiles/BWA>
  25. VanRie A, Page-Ship L, Scott L, Sanne I, Stevens W. (2010). Xpert MTB/ RIF for point-of-care diagnosis of tuberculosis in high HIV burden, resource-limited countries: Hype or hope. Expert Rev Mol Diagn., 10: 937-946.
  26. World Health Organization Global Tuberculosis Report (2016). WHO/HTM/TB2016.13. Geneva. WHO. Available from www.who.int/tb/publications/global_report/en/
  27. WHO. Global Tuberculosis Report (2017). Available from www.who.int
  28. WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. (2008). Anti-Tuberculosis Drug Resistance in the World. Geneva: WHO
How to Cite

O.F., D., S.J., N., A.T, A., B.O., A., K.A, O., K., A., & S, C. (2020). Prevalence of Rifampicin Resistance among Presumptive Pulmonary Tuberculosis Patients within Lagos and its Environs in South-Western Nigeria. Nigerian Journal of Microbiology, 34(1), 5188-5196. https://doi.org/10.67614/njm.2020.uv6dair4

D. O.F., N. S.J., A. A.T, A. B.O., O. K.A, A. K., and C. S, "Prevalence of Rifampicin Resistance among Presumptive Pulmonary Tuberculosis Patients within Lagos and its Environs in South-Western Nigeria," Nigerian Journal of Microbiology, vol. 34, no. 1, pp. 5188-5196, June 2020. doi: 10.67614/njm.2020.uv6dair4

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles